Drugs / mRNA-1982
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05975099 | Jul 2023 → May 2025 | Lyme disease | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07561294 | Apr 2026 → Nov 2028 expected | Lyme disease | ModernaTX, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1982 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05975099 ↗ |
| Known as | SR1 | “SR1” NCT05975099 ↗ |
| Modality | Messenger RNA (mRNA) | “The monovalent and the heptavalent OspA mRNA vaccines (mRNA-1982 and mRNA-1975, respectively) are currently undergoing testing in a Phase 1 clinical trial (NCT05975099).” PMID 42086599 ↗ May 2026 |
| Route | Intramuscular | “as an intramuscular injection” NCT07561294 ↗ |